Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
(201)-510-0950